U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C11H14N2O2
Molecular Weight 206.2411
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PHENETURIDE

SMILES

CCC(C(=O)NC(N)=O)C1=CC=CC=C1

InChI

InChIKey=AJOQSQHYDOFIOX-UHFFFAOYSA-N
InChI=1S/C11H14N2O2/c1-2-9(10(14)13-11(12)15)8-6-4-3-5-7-8/h3-7,9H,2H2,1H3,(H3,12,13,14,15)

HIDE SMILES / InChI
Molecular Formula C11H14N2O2
Molecular Weight 206.2411
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/529017

Pheneturide ((brand names Benuride, Deturid, Pheneturid, Septotence, Trinuride), a decarboxylation product of phenobarbital, has been shown to be an effective drug against seizures, and in particular psychomotor seizures. It has being marketed in Europe, including in Poland, Spain, and the United Kingdom. Pheneturide is supplied in compressed tablets each containing 200 mg. of the drug. It can also be obtained in compound tablets (" trinuride ') each of which contain 200 mg. of pheneturide, 40 mg. of diphenylhydantoin, and 15 mg. of phenobarbitone. Animal experiments have shown that pheneturide protects against drug-induced and electrically induced convulsions.

CNS Activity

Approval Year

Unknown
149124
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
Laburide

Approved Use

Indications: epilepsy
Doses

Doses

DosePopulationAdverse events​
200 mg 5 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 5 times / day
Route: oral
Route: multiple
Dose: 200 mg, 5 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6083365/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/6083365/
Disc. AE: Trance, Constipation...
Other AEs: Drowsiness, Ataxia...
AEs leading to
discontinuation/dose reduction:
Trance (2.27%)
Constipation (2.27%)
Erythematous rash (2.27%)
Other AEs:
Drowsiness (29.5%)
Ataxia (29.5%)
Anorexia (4.5%)
Dysarthria (4.5%)
Vertigo (4.5%)
Headache (4.5%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/6083365/
200 mg 3 times / day multiple, oral
Studied dose
Dose: 200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 200 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6819339/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/6819339/
Other AEs: Drowsiness, Depression...
Other AEs:
Drowsiness
Depression
Rash (18.75%)
Headache (16.7%)
Dizziness (20.8%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/6819339/
AEs

AEs

AESignificanceDosePopulation
Constipation 2.27%
Disc. AE
200 mg 5 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 5 times / day
Route: oral
Route: multiple
Dose: 200 mg, 5 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6083365/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/6083365/
Erythematous rash 2.27%
Disc. AE
200 mg 5 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 5 times / day
Route: oral
Route: multiple
Dose: 200 mg, 5 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6083365/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/6083365/
Trance 2.27%
Disc. AE
200 mg 5 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 5 times / day
Route: oral
Route: multiple
Dose: 200 mg, 5 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6083365/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/6083365/
Ataxia 29.5%
200 mg 5 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 5 times / day
Route: oral
Route: multiple
Dose: 200 mg, 5 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6083365/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/6083365/
Drowsiness 29.5%
200 mg 5 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 5 times / day
Route: oral
Route: multiple
Dose: 200 mg, 5 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6083365/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/6083365/
Anorexia 4.5%
200 mg 5 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 5 times / day
Route: oral
Route: multiple
Dose: 200 mg, 5 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6083365/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/6083365/
Dysarthria 4.5%
200 mg 5 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 5 times / day
Route: oral
Route: multiple
Dose: 200 mg, 5 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6083365/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/6083365/
Headache 4.5%
200 mg 5 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 5 times / day
Route: oral
Route: multiple
Dose: 200 mg, 5 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6083365/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/6083365/
Vertigo 4.5%
200 mg 5 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 5 times / day
Route: oral
Route: multiple
Dose: 200 mg, 5 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6083365/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/6083365/
Depression
200 mg 3 times / day multiple, oral
Studied dose
Dose: 200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 200 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6819339/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/6819339/
Drowsiness
200 mg 3 times / day multiple, oral
Studied dose
Dose: 200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 200 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6819339/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/6819339/
Headache 16.7%
200 mg 3 times / day multiple, oral
Studied dose
Dose: 200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 200 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6819339/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/6819339/
Rash 18.75%
200 mg 3 times / day multiple, oral
Studied dose
Dose: 200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 200 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6819339/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/6819339/
Dizziness 20.8%
200 mg 3 times / day multiple, oral
Studied dose
Dose: 200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 200 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6819339/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/6819339/
PubMed

PubMed

TitleDatePubMed
Therapeutic drug monitoring of old and newer anti-epileptic drugs.
2004
Patents

Patents

US20130281410
1
US8563038
1

Sample Use Guides

In Vivo Use Guide
The recommended daily dose of the drug in adults is 600-800 mg.,
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:28:15 GMT 2025
Edited
by admin
on Mon Mar 31 18:28:15 GMT 2025
Record UNII
878CEJ4HGX
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PHENETURIDE
INN   MART.   MI   WHO-DD  
INN  
Official Name English
ETHYLPHENACEMIDE
JAN  
Preferred Name English
BENURIDE
Brand Name English
N-(.ALPHA.-PHENYLBUTYRYL)UREA
Systematic Name English
M-551
Code English
PHENURIDE
Common Name English
.ALPHA.-PHENYL-.ALPHA.-ETHYLACETYLUREA
Systematic Name English
UREA, (2-PHENYLBUTYRYL)-
Systematic Name English
PHENETURIDE [MART.]
Common Name English
pheneturide [INN]
Common Name English
DL-PHENETURIDE
Common Name English
Pheneturide [WHO-DD]
Common Name English
ETHYLPHENYLACETYLUREA
Systematic Name English
PHENETURIDE [MI]
Common Name English
S-46
Code English
2-PHENYLBUTYRYLUREA
Systematic Name English
1-((ETHYL)PHENYLACETYL)UREA
Systematic Name English
LIRCAPYL
Brand Name English
ETHYLPHENACEMIDE [JAN]
Common Name English
PBU
Code English
PHENYLETHYLACETYLUREA
Systematic Name English
Classification Tree Code System Code
WHO-VATC QN03AX13
Created by admin on Mon Mar 31 18:28:15 GMT 2025 , Edited by admin on Mon Mar 31 18:28:15 GMT 2025
NCI_THESAURUS C264
Created by admin on Mon Mar 31 18:28:15 GMT 2025 , Edited by admin on Mon Mar 31 18:28:15 GMT 2025
WHO-ATC N03AX13
Created by admin on Mon Mar 31 18:28:15 GMT 2025 , Edited by admin on Mon Mar 31 18:28:15 GMT 2025
Code System Code Type Description
MERCK INDEX
m8614
Created by admin on Mon Mar 31 18:28:15 GMT 2025 , Edited by admin on Mon Mar 31 18:28:15 GMT 2025
PRIMARY Merck Index
MESH
C005825
Created by admin on Mon Mar 31 18:28:15 GMT 2025 , Edited by admin on Mon Mar 31 18:28:15 GMT 2025
PRIMARY
ChEMBL
CHEMBL2107062
Created by admin on Mon Mar 31 18:28:15 GMT 2025 , Edited by admin on Mon Mar 31 18:28:15 GMT 2025
PRIMARY
SMS_ID
100000082233
Created by admin on Mon Mar 31 18:28:15 GMT 2025 , Edited by admin on Mon Mar 31 18:28:15 GMT 2025
PRIMARY
FDA UNII
878CEJ4HGX
Created by admin on Mon Mar 31 18:28:15 GMT 2025 , Edited by admin on Mon Mar 31 18:28:15 GMT 2025
PRIMARY
EVMPD
SUB09760MIG
Created by admin on Mon Mar 31 18:28:15 GMT 2025 , Edited by admin on Mon Mar 31 18:28:15 GMT 2025
PRIMARY
NCI_THESAURUS
C72826
Created by admin on Mon Mar 31 18:28:15 GMT 2025 , Edited by admin on Mon Mar 31 18:28:15 GMT 2025
PRIMARY
DRUG CENTRAL
2125
Created by admin on Mon Mar 31 18:28:15 GMT 2025 , Edited by admin on Mon Mar 31 18:28:15 GMT 2025
PRIMARY
CAS
90-49-3
Created by admin on Mon Mar 31 18:28:15 GMT 2025 , Edited by admin on Mon Mar 31 18:28:15 GMT 2025
PRIMARY
DRUG BANK
DB13362
Created by admin on Mon Mar 31 18:28:15 GMT 2025 , Edited by admin on Mon Mar 31 18:28:15 GMT 2025
PRIMARY
WIKIPEDIA
PHENETURIDE
Created by admin on Mon Mar 31 18:28:15 GMT 2025 , Edited by admin on Mon Mar 31 18:28:15 GMT 2025
PRIMARY
PUBCHEM
72060
Created by admin on Mon Mar 31 18:28:15 GMT 2025 , Edited by admin on Mon Mar 31 18:28:15 GMT 2025
PRIMARY
CAS
6509-31-5
Created by admin on Mon Mar 31 18:28:15 GMT 2025 , Edited by admin on Mon Mar 31 18:28:15 GMT 2025
SUPERSEDED
EPA CompTox
DTXSID4020612
Created by admin on Mon Mar 31 18:28:15 GMT 2025 , Edited by admin on Mon Mar 31 18:28:15 GMT 2025
PRIMARY
INN
648
Created by admin on Mon Mar 31 18:28:15 GMT 2025 , Edited by admin on Mon Mar 31 18:28:15 GMT 2025
PRIMARY
ECHA (EC/EINECS)
201-998-2
Created by admin on Mon Mar 31 18:28:15 GMT 2025 , Edited by admin on Mon Mar 31 18:28:15 GMT 2025
PRIMARY
Related Record Type Details
Structure of PHENETURIDE
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966